Single-cell multiomics

ASCEND offers services from initial project planning to completed and ready to analyze data output and bioinformatics assistance with all steps in-between. We aim to collaboratively facilitate your research and provide broad expertise across organ and model systems.

Visit 10x Genomics for more information on available assays.

Spatial transcriptomics

ASCEND will provide experimental planning and full workflow to data analysis driven by state-of-the-art automated seqFISH technology, highly developed imaging algorithms and image analysis expertise.

Visit Spatial Genomics for details on the device/technology and schedule a consultation with us for more information. (Expected consultations starting in November 2024 and experiment timeslots starting in January 2025)

                                                                      Lineage competent iPSCs

ASCEND has an expanding series of human pluripotent cell lines, e.g., WTB, WTC, and WTC-CAG-spCas9—a modified WTC with constitutive Cas9 expression. Both WTB and WTC were reprogrammed from skin fibroblast samples taken from healthy adults of diverse backgrounds: WTC from a Japanese male and WTB from a Hispanic female. Both cell lines have been whole genome sequenced, and donors have consented to public sharing of this sequencing data, which is available to researchers utilizing these lines or their derivatives. All lines are under an MTA negotiated for broad use, including the production and sharing of cell derivatives for research use. In our facility, these cells are quality controlled via regular mycoplasma testing, G-Banding karyotype analysis, and a trilineage differentiation assay.